Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Horizon Announces Oncology Drug Discovery Collaboration with AstraZeneca

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Agreement to explore Horizon’s first-in-class kinase target programme, HD-001.

Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.

The HD-001 program, currently in the early stages of drug discovery, has the potential to be developed into a treatment based on modulation of a novel kinase.

This target has been shown to be mutated in a range of cancer types including colon and lung. Importantly, the target has also been shown to play a key role in K-Ras mutant tumours.

K-Ras is mutated in up to 40% of all cancer types causing resistance to many of the available targeted therapeutics and as a result is associated with poor patient outcomes, which makes the development of molecular targeted therapies against the gene a significant unmet need.

Dr Chris Torrance, CSO and leader of the HD-001 program at Horizon, commented: “Targeting cancer cells harboring mutant K-Ras has been a perennial issue for the drug discovery community, with few canonical pathway or ‘gene-addiction’ targets showing a clear benefit on this important cancer gene. We are excited to partner with Astra Zeneca on the development of HD-001, as they have shown a firm commitment to the identification of novel K-Ras targets.”

Dr Darrin M Disley, CEO at Horizon Discovery, said: “The program has benefitted greatly from the use of Horizon’s drug discovery toolbox to first exquisitely validate the target and then provide a range of ‘on-target’ cellular assays to support rational drug discovery. As a result, the lead discovery effort has been rapid, resulting in a diverse portfolio of potent and selective inhibitors of the target. The novelty of the target combined with the unique suite of biological and chemical tools assembled will provide AstraZeneca with a strong base to launch its pre-clinical and clinical research efforts; supported in the early stages by our own research scientists.”

Susan Galbraith, Head of the Oncology Innovative Medicines Unit at AstraZeneca, said: “Horizon’s novel kinase target programme coupled with their target validation technology allows us to broaden our oncology research efforts beyond our own internal capabilities. AstraZeneca has a proven track record of collaborating on early stage discovery projects with innovative organizations like Horizon, partnering their cutting-edge science with our strong oncology expertise to bring new medicines to cancer patients.”

Under the terms of the agreement, Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totaling up to $75M, as well as tiered royalties.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon and Domainex Collaborate to Support Lead Optimization Oncology Program
Horizon’s isogenic cell lines accurately modeling tumor mutations to be used to profile lead compounds.
Tuesday, August 07, 2012
Horizon and University of Leicester Form CoE in rAAV-mediated Genome Editing
Collaboration will focus on developing isogenic models of cardiovascular disease.
Monday, July 16, 2012
Horizon and H3 Biomedicine to Collaborate
H3 Biomedicine to employ Horizon’s unique gene editing technology and isogenic cell lines to validate genetically defined drug targets for development of cancer therapeutics.
Friday, May 04, 2012
Horizon Announces Strategic Partnership with Promega
Partnership to combine Horizon’s genome editing technology with Promega’s reporter technologies to enable personalized drug development.
Tuesday, November 08, 2011
University of Liverpool Scientists to Mine Horizon’s Patient Models for Novel Protein Targets and Biomarkers
The collaboration will identify and validate novel cancer targets and biomarkers for personalized cancer therapy and diagnostics.
Monday, October 19, 2009
Horizon Discovery Sign Commercial Screening Agreement with Silicos
Agreement covers testing of Silicos lead compounds on human isogenic cell-lines comprising specific genotypes targeted by the compound series.
Tuesday, August 25, 2009
Horizon Discovery Sign Worldwide Exclusive License to new Inventions from University of Torino
License relates to the use of human isogenic cell-lines in predicting the response of drugs targeted at the genetic make-up of individual cancer patients.
Tuesday, August 11, 2009
Horizon Discovery Sign Screening Agreement with Actelion Pharmaceuticals
The agreement covers the screening of a number of Actelion lead compounds on a wide panel of genotypes using Horizon’s X-MAN cell-line technology.
Thursday, December 18, 2008
The X-MAN Steps-Out: Horizon Discovery Sign Screening and License Agreements with Agios Pharmaceuticals
Horizon Discovery (Horizon) today announced it has signed two commercial agreements with a ground-breaking U.S. cancer start-up; Agios Pharmaceuticals (Agios), relating to its X-MAN technology.
Wednesday, October 01, 2008
Horizon Discovery Sign Screening and License Agreements with Agios Pharmaceuticals
The agreements cover the licensing of certain X-MAN cell lines and the screening of a number of Agios lead compounds on a wide panel of genotypes.
Wednesday, October 01, 2008
Scientific News
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
Versatile New Molecule-Building Technique
Chemists at The Scripps Research Institute (TSRI) have devised a new and widely applicable technique for building potential drug molecules and other organic compounds.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!